On 16 May 2025, the FDA cleared the first blood-based test for diagnosing Alzheimer’s disease—a major shift in how we detect the condition. Developed by Fujirebio Diagnostics, the Lumipulse test offers a simpler, faster, and less invasive alternative to PET scans and spinal taps, bringing early detection within easier reach for patients showing signs of cognitive decline. 

In the crowded corridors of medtech innovation, it's easy to get swept up in buzzwords—AI-powered, minimally invasive, precision diagnostics. But every now and then, a company emerges with more than just jargon—it comes armed with transformative tech, a clear path to market, and the traction to back it up.

When it comes to spotting undervalued potential in biotech, I often look for companies that are not only developing novel technologies but also demonstrating clear paths to commercialisation. This month, three small-cap names on the ASX have really caught my attention: Memphasys Limited (ASX: MEM), Control Bionics (ASX: CBL), and dorsaVi Ltd (ASX: DVL). Each is on a very different mission, but all three are making measurable progress—and investors are starting to notice.

At Samso, we often talk about “first movers” and “market makers” in the mining and tech sectors. But when it comes to mental health care, particularly treatment-resistant conditions like Post-traumatic stress disorder (PTSD), the stakes aren’t just commercial. They’re deeply personal.

Let’s be honest: endometriosis has long been one of the most underdiagnosed and misunderstood medical conditions in women's health. A silent disruptor, it causes pain, fertility issues, and decades-long suffering, often without a name. Until now, the only path to a diagnosis was invasive laparoscopic surgery, usually after seven years of misdiagnosis. That’s not a system built for healing. But what if we could change that narrative with a simple blood test?

Let’s be honest: endometriosis has long been one of the most underdiagnosed and misunderstood medical conditions in women's health. A silent disruptor, it causes pain, fertility issues, and decades-long suffering, often without a name. Until now, the only path to a diagnosis was invasive laparoscopic surgery, usually after seven years of misdiagnosis. That’s not a system built for healing. But what if we could change that narrative with a simple blood test?

In a world grappling with stress and sleeplessness, The Calmer Co. International Limited (ASX: CCO) is emerging as a standout in the wellness beverage market. This Brisbane-based company, known for its innovative kava-infused offerings, has just posted a headline-grabbing 104% year-on-year growth in Amazon USA sales, reaching AUD $203,000 in April 2025 alone.

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) has made a decisive move with its proposed acquisition of StemSmart™, a patented mesenchymal stromal cell (MSC) technology. This isn’t just another biotech transaction — it signals a strategic leap into the fast-growing field of regenerative medicine, positioning NSB to capitalise on one of the most promising frontiers in modern healthcare.

Emyria Limited (ASX: EMD) embodies the fusion of compassionate care, groundbreaking science, and a market in dire need of change. Recently, the company has gained attention by uniquely creating a scalable, evidence-based model for psychedelic-assisted therapy within licensed medical settings in Australia.

Melbourne-based biotech innovator Algorae Pharmaceuticals (ASX: 1AI) is setting the stage for a game-changing therapeutic breakthrough with its combination drug candidate, AI-116, aimed at treating dementia and neurodegenerative disorders.

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has unveiled compelling Phase 2 clinical trial data for its lead drug candidate, ATH434—a major advancement in treating Multiple System Atrophy (MSA). The findings were presented at the prestigious European MSA Symposium in London, drawing attention from global experts in neurodegenerative research.

Actinogen Medical Limited (ASX: ACW) is advancing one of the most promising neuroscience drug candidates in the global biotech pipeline. With its novel oral drug Xanamem® (emestedastat), the company is targeting two of the largest and most urgent unmet needs in modern medicine: Alzheimer’s disease (AD) and Major Depressive Disorder (MDD).

This is a great start for WOA as this is a crucial phase in its global growth strategy. In entering into an exclusive distribution and offtake agreement with Univar Solutions China, a branch of the world's second-largest distributor of chemicals and ingredients, this gives WOA a direct route into a massive market.

Coffee with Samso Episode 204 is all about Lupins and Lupin Protein Isolate.

Mach7 Technologies (ASX: M7T), a leader in medical imaging software, continues to show impressive growth and strategic refinement under the